6 analysts have shared their evaluations of Crinetics Pharmaceuticals CRNX during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.0, a high estimate of $52.00, and a low estimate of $42.00. This upward trend is evident, with the current average reflecting a 8.89% increase from the previous average price target of $45.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Crinetics Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Skorney | Baird | Raises | Outperform | $52.00 | $45.00 |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $50.00 | - |
| Jeffrey Hung | Morgan Stanley | Announces | Overweight | $50.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $50.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $42.00 | - |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $50.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crinetics Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Crinetics Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Crinetics Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
To gain a panoramic view of Crinetics Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Crinetics Pharmaceuticals analyst ratings.
Delving into Crinetics Pharmaceuticals's Background
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
A Deep Dive into Crinetics Pharmaceuticals's Financials
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Negative Revenue Trend: Examining Crinetics Pharmaceuticals's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -24.45% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Crinetics Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -16606.36%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crinetics Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.33%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Crinetics Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -12.29%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Crinetics Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 0.1. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
